Cardiac Contractility Modulation is an innovative therapy intended for the treatment of patients with heart failure (NYHA class III/IV) and LVEF 25-45, without an indication for CRT and with symptoms despite GDMT.
The Cardiac Contractility Modulation treatment is delivered by a rechargeable pacemaker-like device that applies non-excitatory electrical signals during the absolute refractory period in the patient’s cardiac cycle. Unlike cardiac pacing, Cardiac Contractility Modulation does not affect the cardiac rhythm.
The use of this innovative therapy may enhance the strength of ventricular contraction and therefore the heart’s pumping capacity by modulating the myocardial contractility.
Patients easily recharge the IPG unit on a weekly basis, using a portable, home-based charger system.